Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients with Stage I-III Breast Cancer

Inclusion Criteria

• Women diagnosed with breast cancer stages I-III initiating first line adjuvant or neoadjuvant doxorubicin hydrochloride (DOX) chemotherapy or other chemotherapy for breast cancer
• Ability to understand English and read and write at the 8th grade level and give a written informed consent document
• For additional cohort, women with breast cancer stages I-III who currently on or within 18 months of completing first line adjuvant or neoadjuvant DOX chemotherapy or other chemotherapy for breast cancer

Exclusion Criteria

• Rheumatoid arthritis and other types of autoimmune and inflammatory joint disease, with the exception of osteoarthritis and fibromyalgia
• Concurrent other malignancy or metastatic malignancy of any kind
• Known bleeding disorders
• Current use of warfarin or other anticoagulants
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
• Pregnant or nursing women
• Unable to give informed consent
• Tetracycline allergy
• Patient is able to opt out of magnetic resonance imaging (MRI)/PET examination if there are any contraindications to examinations including, but not limited to, refusal to participate, ferromagnetic metal in the body, pacemaker or severe claustrophobia